We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BaroFold Grants Protein Technology Research License to Pfizer
News

BaroFold Grants Protein Technology Research License to Pfizer

BaroFold Grants Protein Technology Research License to Pfizer
News

BaroFold Grants Protein Technology Research License to Pfizer

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BaroFold Grants Protein Technology Research License to Pfizer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BaroFold, Inc. has announced the granting of a multi-site research license to Pfizer, Inc. for BaroFold's proprietary PreEMT™ high pressure technology for solubilizing, disaggregating and refolding proteins.

Financial terms were not disclosed. Pfizer joins several other biotechnology firms and pharmaceutical corporations who have licensed BaroFold's technology to refold and produce proteins.

"We are pleased to be working with Pfizer, a global leader in discovering and developing breakthrough medicines," said Lyndal Hesterberg, President and CEO of BaroFold Inc.

"The use of the BaroFold technology has broken a log-jam for many companies in target discovery for developing clean three-dimensional protein structures for crystallography and rational drug design. PreEMT technology has been validated by various partners through use in over two hundred proteins. We hope to support future development of important therapeutic programs at Pfizer."

Advertisement